Melanoma-associated antigen peptide-major histocompatibility complex (pMHC) (pMHC)

Peptide–Major Histocompatibility Complex (pMHC) complexes presenting melanoma-associated antigens are critical immunological targets located on the surface of tumor cells. These complexes are formed when intracellular proteins, such as gp100, MART-1, or MAGE-A4, are degraded into short peptides and loaded onto MHC Class I molecules (typically HLA-A*02:01) for presentation to CD8+ T cells [1][2]. In the context of melanoma, these pMHCs act as molecular signatures that distinguish malignant cells from healthy ones, making them ideal targets for immunotherapy [3]. Therapeutic interventions like T-cell receptor (TCR) engineered T-cells and bispecific T-cell engagers (e.g., Tebentafusp) are designed to bind these specific peptide-HLA combinations with high affinity [4]. This binding triggers a potent cytotoxic immune response, leading to the selective destruction of melanoma cells [5]. However, the efficacy of these therapies is often limited to patients with specific HLA types and can be hindered by tumor-mediated downregulation of MHC expression [6].

Other names

Melanoma-associated pMHCTumor-specific peptide-HLA complexMelanoma antigen-MHC complexpMHC-IAntigen-HLA complex

T-cell receptor (TCR) mediated recognition of specific peptide-HLA complexes, leading to T-cell redirection and cytotoxic T-lymphocyte-mediated lysis of tumor cells.